心血管疾病在世界范围内是死亡的主因之一.生活方式的改变以及低密度脂蛋白胆固醇( LDL-C)的增加仍然是心血管疾病的重要危险因素.尽管他汀类降低LDL-C已被证实可有效减少心血管疾病的发病率,但仍不能满足临床治疗需求.非诺贝特酸是最新的剂型,在降脂和非降脂方面作用明显,不仅能克服老的贝特类药物的缺陷,还可根据药代动力学的性质作单一疗法或联合他汀类使用,是与他汀类联合用药中最合理有效的贝特类药物.%Cardiovascular disease ( CVD) is the leading cause of mortality worldwide. Lifestyle modifications, along with low-density lipoprotein cholesterol ( LDL-C) reduction, remain the highest priorities in CVD risk management. For LDL-C reduction, statins are the most effective and have demonstrated incremental benefits in CVD risk reduction. However, there is a need for additional measures. Fenofibric acid is the newest available option. It not only overcomes the drawbacks of older fibrates, particularly in terms of pharmacokinetic properties, but it has also been shown to be the most suitable fibrate to combine with a statin.
展开▼
